QureBio has raised about 200 million yuan ($31 million) in its Series B round of financing, while Galaxy Future Technology has secured $10 million in its angel and angel+ rounds.
QureBio nabs nearly $31m in Series B
Biopharmaceutical firm QureBio has secured approximately 200 million yuan ($31 million) in its Series B round led by the affiliate industry fund of Bank of Communications’ BOCOM International.
Other investors who joined the round include Oriza Holdings, Spinnotec, Longmen Capital, Tianfu Sanjiang Capital, among others. Boutique investment bank WinX Capital facilitated the transaction, per a statement.
QureBio, headquartered in Shanghai, was incubated as an innovative drug discovery and development platform in 2017. It focuses on diseases such as tumors, autoimmune and metabolic disorders.
“We will continue to focus on the research and development of innovative drugs based on our proprietary platforms,” said QureBio founder Xiangdong Qu in a statement.
Matrix backs Galaxy Future Technology
Galaxy Future Technology, a specialist in cloud computing software, has raised $10 million in its angel and angel+ rounds of financing.
According to its statement, the first tranche of angel rounds was led by Future Capital that also saw the participation of Chuxin Capital. Meanwhile, the company’s angel+ round was led by Matrix Partners China and joined by Future Capital and Chuxin Capital. In addition, two individual investors PingCAP CTO Dongxu Huang and Agora vice president Ting He also pumped in capital.
Galaxy plans to use the corpus to advance its talent pool, pipeline products and markets.